Page 108 - Read Online

Page 16 of 20 Rhoades et al. J Transl Genet Genom 2019;3:1. I https://doi.org/10.20517/jtgg.2018.26

Authors’ contributions
Idea conception, literature research and manuscript revision: Rhoades R, Jackson F, Teng S
Manuscript writing and editing: Rhoades R, Teng S

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by the Howard University startup funds (U100193). It was supported (in part)
by the National Institute on Minority Health and Health Disparities of the National Institutes of Health
under Award Number G12MD007597. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of Health.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

RefeReNCes
1. Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis
approach. Psychol Med 2006;36:1535-40.
2. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, et al. The economic burden of schizophrenia in the United States in 2002. J Clin
Psychiatry 2005;66:1122-9.
3. Cloutier M, Aigbogun MS, Guerin A, Nitulescu R, Ramanakumar AV, et al. The economic burden of schizophrenia in the United States in
2013. J Clin Psychiatry 2016;77:764-71.
4. Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician 2007;75:1821-9.
5. Millier A, Schmidt U, Angermeyer MC, Chauhan D, Murthy V, et al. Humanistic burden in schizophrenia: a literature review. J Psychiatr
Res 2014;54:85-93.
6. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, et al. Glutamate in schizophrenia: a focused review and meta-analysis
of 1H-MRS studies. Schizophr Bull 2013;39:120-9.
7. Plitman E, Nakajima S, de la Fuente-Sandoval C, Gerretsen P, Chakravarty MM, et al. Glutamate-mediated excitotoxicity in schizophrenia:
a review. Eur Neuropsychopharmacol 2014;24:1591-605.
8. Egerton A, Modinos G, Ferrera D, McGuire P. Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis.
Transl Psychiatry 2017;7:e1147.
9. Van Den Heuvel MP, Fornito A. Brain networks in schizophrenia. Neuropsychol Rev 2014;24:32-48.
10. Morgan C, Fisher H. Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma - a critical review.
Schizophr Bull 2007;33:3-10.
11. Cannon TD, Kaprio J, Lönnqvist J, Huttunen M, Koskenvuo M. The genetic epidemiology of schizophrenia in a Finnish twin cohort: a
population-based modeling study. Arch Gen Psychiatry 1998;55:67-74.
12. Keller MC, Miller G. Resolving the paradox of common, harmful, heritable mental disorders: which evolutionary genetic models work
best? Behav Brain Sci 2006;29:385-404.
13. Kim Y, Zerwas S, Trace SE, Sullivan PF. Schizophrenia genetics: where next? Schizophr Bull 2011;37:456-63.
14. International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, et al. Common polygenic variation contributes to
risk of schizophrenia and bipolar disorder. Nature 2009;460:748-52.
15. Chan MK, Cooper JD, Heilmann-Heimbach S, Frank J, Witt SH, et al. Associations between SNPs and immune-related circulating proteins
in schizophrenia. Sci Rep 2017;7:12586
16. Hawi Z, Tong J, Dark C, Yates H, Johnson B, et al. The role of cadherin genes in five major psychiatric disorders: a literature update. Am J